Immunovant, Inc. (IMVT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$902.1M
Cash & Equivalents
$407.3M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$8,153M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase2 Readout | — |
| 2027-05-01 | Phase2 Readout | — |
Active Clinical Trials (11)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants... | PHASE3 | Active Not Recruiting | 240 |
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | PHASE3 | Recruiting | 231 |
| NCT06727604 | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' D... | PHASE2 | Recruiting | 240 |
| NCT06980805 | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus... | PHASE2 | Active Not Recruiting | 56 |
| NCT07018323 | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' D... | PHASE2 | Recruiting | 210 |
| NCT06754462 | A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to ... | PHASE2 | Active Not Recruiting | 120 |
| NCT07032662 | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | PHASE2 | Recruiting | 162 |
| NCT07286006 | A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) | PHASE2 | Enrolling By Invitation | 372 |
| NCT07188844 | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy... | PHASE2 | Enrolling By Invitation | 108 |
| NCT05581199 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | PHASE2 | Active Not Recruiting | 277 |
| NCT06979531 | Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic D... | PHASE2 | Recruiting | 180 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.